Legis Daily

To amend the Federal Food, Drug, and Cosmetic Act to prevent the abuse of dextromethorphan, and for other purposes.

USA115th CongressHR-1271| House 
| Updated: 3/17/2017
Bill Johnson

Bill Johnson

Republican Representative

Ohio

Cosponsors (6)
Paul Tonko (Democratic)Patrick Meehan (Republican)Doris O. Matsui (Democratic)Ron Kind (Democratic)Yvette D. Clarke (Democratic)Alcee L. Hastings (Democratic)

Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
DXM Abuse Prevention Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to: (1) require a retailer that sells certain drugs containing dextromethorphan (DXM) to have a verification system that is intended to ensure that no one under 18 years of age purchases such drugs from the retailer, (2) establish other restrictions on the sale of over-the-counter drugs containing DXM, and (3) establish restrictions on the distribution of bulk DXM.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 1, 2017
Introduced in House
Mar 1, 2017
Referred to the House Committee on Energy and Commerce.
Mar 17, 2017
Referred to the Subcommittee on Health.
  • March 1, 2017
    Introduced in House


  • March 1, 2017
    Referred to the House Committee on Energy and Commerce.


  • March 17, 2017
    Referred to the Subcommittee on Health.

Health

Child healthCivil actions and liabilityDrug, alcohol, tobacco useDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsPrescription drugsRetail and wholesale trades

To amend the Federal Food, Drug, and Cosmetic Act to prevent the abuse of dextromethorphan, and for other purposes.

USA115th CongressHR-1271| House 
| Updated: 3/17/2017
DXM Abuse Prevention Act of 2017 This bill amends the Federal Food, Drug, and Cosmetic Act to: (1) require a retailer that sells certain drugs containing dextromethorphan (DXM) to have a verification system that is intended to ensure that no one under 18 years of age purchases such drugs from the retailer, (2) establish other restrictions on the sale of over-the-counter drugs containing DXM, and (3) establish restrictions on the distribution of bulk DXM.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Mar 1, 2017
Introduced in House
Mar 1, 2017
Referred to the House Committee on Energy and Commerce.
Mar 17, 2017
Referred to the Subcommittee on Health.
  • March 1, 2017
    Introduced in House


  • March 1, 2017
    Referred to the House Committee on Energy and Commerce.


  • March 17, 2017
    Referred to the Subcommittee on Health.
Bill Johnson

Bill Johnson

Republican Representative

Ohio

Cosponsors (6)
Paul Tonko (Democratic)Patrick Meehan (Republican)Doris O. Matsui (Democratic)Ron Kind (Democratic)Yvette D. Clarke (Democratic)Alcee L. Hastings (Democratic)

Health Subcommittee, Energy and Commerce Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Child healthCivil actions and liabilityDrug, alcohol, tobacco useDrug safety, medical device, and laboratory regulationDrug trafficking and controlled substancesLicensing and registrationsPrescription drugsRetail and wholesale trades